Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service, Trade Show

Aurora Bio, Inc. Announces Clinical Data on Lead Program, AUR01, a Novel Systemic Amyloidosis Imaging Tracer, at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition

Aurora Bio, Inc. www.Aurorabioinc.com today announced that data for the company's novel PET radiotracer, AUR01, in development for systemic amyloidosis, has been accepted for presentation at the upcoming 61st American Society of Hematology (ASH) annual meeting, to be held December 7 ? 10, 2019, in Orlando, FL. Abstract highlights and presentation details are outlined below.

Spencer Guthrie, Chief Executive Officer, stated, "We are looking forward to an exciting ASH conference as we present our initial data highlighting the unique ability of AUR01 to detect and potentially monitor whole body amyloid burden in systemic amyloid diseases. The unmet need for early and accurate diagnosis for systemic amyloidosis is significant as many patients are getting diagnosed too late to obtain optimal benefit from treatment. There is currently no approved diagnostic, no agent that can detect whole body amyloid burden and no method for directly measuring change in amyloid pathology in treated patients. We believe this compound has the potential to change the way systemic amyloidosis is diagnosed and monitored and holds great potential to provide for efficient drug development for new targeted therapeutics, including Aurora Bio's own therapeutic programs."

Poster Presentation: https://ash.confex.com/ash/2019/webprogram/Paper128850.html

Presentation Details

3034 Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124I-p5+14, for Imaging Systemic Amyloidosis


Aurora Bio is a clinical stage biopharmaceutical company developing a platform of immunotherapies and an imaging diagnostic for multiple systemic amyloid diseases, including AL, ATTR and ALECT2 amyloidosis. The diagnostic imaging agent is currently in Phase 1 with a planned Ph 3 to potentially initiate in 2020. The company also has 2 pre-clinical stage therapeutic programs being developed for a broad range of systemic amyloid diseases. The immunotherapies consist of a peptide-fusion protein as well as cell therapy utilizing engineered macrophages (CAR-M) to remove amyloid. Currently, there are no approved treatments for 29 out of 30 systemic amyloid diseases While approved therapies in ATTR, and those in development for AL an ATTR, target the pre-cursor protein of individual amyloid diseases, Aurora Bio's goal is to develop immunotherapies that treat across all systemic amyloid diseases. Aurora Bio, Inc. is based in South San Francisco, CA www.aurorabioinc.com

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

These press releases may also interest you

at 08:54
Remind, the leading communication platform in education, today announced the YMCA of Metro Chicago as a major new enterprise customer. With 18 YMCAs in the Chicagoland area, the Y plans to use Remind to support communication for more than 7,000...

at 08:53
CARFAX® now helps insurers more precisely identify a specific vehicle's trim level and installed equipment, allowing them to more accurately underwrite and price auto policies. As part of CARFAX Vehicle History, insurers can now access information on...

at 08:52
ITX Corp., a leading producer of custom software products, announced today the addition of industry veterans Ronald Knauer as Vice President of Sales and Kyle Psaty as Vice President of Marketing. Knauer joins ITX from DXC Technology, in Cincinnati,...

at 08:50
SoftwareReviews, a division of world-class IT research and consulting firm Info-Tech Research Group, announces the publication of its 2020 Big Data Quadrant Awards today, naming three gold medalists based on user reviews. The following vendors are...

at 08:50
The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced the appointment of Skip Irving as chairman of its Board of Directors. Irving's 30-year track record of leadership in the biopharmaceutical industry, including structuring...

at 08:50
GIACT Systems, LLC, the leader in helping companies positively identify and authenticate customers, today announced a new report, The Identity Verification Manual, developed to help automotive dealerships and captive auto finance identify ways to...

News published on 22 november 2019 at 14:20 and distributed by: